Clinical trial

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

NCT03767335

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention MEN1611 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fulvestrant Normalized identity: fulvestrantView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-11-13

PhasePHASE1

Conditions

Advanced or Metastatic Breast Cancerunresolved

Interventions

MEN1611DRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

FulvestrantDRUG · verified · RxNorm: fulvestrant

Sponsors & collaborators

Menarini Grouplead sponsor

Mapped research locations

MadridSpain3 MilanItaly3 BarcelonaSpain2 LondonUnited Kingdom2 BrusselsBelgium2 St LouisMissouri, United States1 ToulouseFrance1 SevilleSpain1 LilleFrance1 ManchesterUnited Kingdom1 LeuvenBelgium1 Fort LauderdaleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03767335 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.